This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Criteria used to ensure the validity of primary studies
Not stated.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The number of primary studies included was approximately 36.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
Prevalence values of different disorders found in patients during upper gastrointestinal endoscopy were: malignancy (2%), reflux esophagitis (16%), peptic ulcers and relevant inflammations (27%), relevant disorders (3%) and functional dyspepsia (52%).46% of patients responded positively to the 2-week omeprazole treatment. 30% of patients relapsed, but responded positively to the 8-week omeprazole treatment. Subsequently, 26% of patients relapsed.20% of patients underwent a third therapy, after which 8% of patients relapsed.62% of patients in the empirical treatment group had upper gastrointestinal endoscopy. During 1 year, 57% of the patients in the control group had symptom relief, compared to 62% of patients in the empirical treatment group. When the percentage of patients with an organic disorder varied between 31% and 61%, the percentage of patients who would have an endoscopy lay between 74% and 49% and the percentage who had symptom relief lay between 61% and 68%.
Measure of benefits used in the economic analysis
The measure of benefits was the percentage of patients with symptom relief.
Direct costs
Direct costs for upper gastrointestinal endoscopy included the materials used, administrative staff and maintenance, the costs of the endoscopy equipment, charges for gastrointestinal endoscopy, charges for laboratory tests and costs for clinical consultation. Costs were not discounted. Costs and quantities were not reported separately. The quantity/cost boundary adopted was that of the health care system. The estimation of quantities and costs was based on actual data. Cost data were based on real costs from the University Hospital Nijmegen.
Statistical analysis of costs
Not included.
